GC Biopharma 2026 Q1 Consolidated Revenue KRW 435.5B, Operating Profit KRW 11.7B… Strong US ALYGLO Sales, Dividend Policy Maintained

Consolidated revenue KRW 435.5B (+13.5% YoY), operating profit KRW 11.7B (turnaround from KRW -4.4B loss in Q1 2025)
US subsidiary GC Biopharma USA revenue KRW 34.9B (vs. KRW 8.6B in Q1 2025, +306%), ALYGLO gaining traction in US market
ABO Holdings plasma revenue KRW 28.5B, 7 plasma centers with FDA approval, additional centers under expansion
R&D: GC1123B (Hunter syndrome) submitted for approval in Peru/Korea, GC1130A (Sanfilippo) Phase 1 ongoing, mRNA vaccine Phase 1, etc.
Dividend policy: Maintained at least KRW 1,500 per share for 2025-2027, returning ≥20% of separate net income
Debt ratio 112%, net debt to equity 58% (slightly improved from year-end)
Consolidated net profit KRW 20.1B, turning around from net loss in Q1 2025